Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases of 402,000 securities of Allergy Therapeutics plc at a price range of 0.0125 to 0.013 per unit. However, there were no sales of securities by Panmure Gordon (UK) Limited. The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions related to Allergy Therapeutics plc.

The disclosure also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer. Additionally, there are no agreements, arrangements, or understandings relating to the voting rights or future acquisition or disposal of any relevant securities of Allergy Therapeutics plc.

The disclosure was made on October 18, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0) 20 7886 2969.

It is important to note that this disclosure is specific to the dealings of Panmure Gordon (UK) Limited and does not provide any other information about Allergy Therapeutics plc or its operations.